12:00 AM
 | 
May 06, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

KB001-A regulatory update

FDA granted Fast Track designation for KB001-A to prevent bacterial pneumonia caused by Pseudomonas aeruginosa in mechanically-ventilated patients. Sanofi is conducting a U.S. Phase I trial of KB001-A for the indication. In January...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >